200 related articles for article (PubMed ID: 19247683)
1. Combinatory inhibition of VEGF and FGF2 is superior to solitary VEGF inhibition in an in vitro model of RPE-induced angiogenesis.
Stahl A; Paschek L; Martin G; Feltgen N; Hansen LL; Agostini HT
Graefes Arch Clin Exp Ophthalmol; 2009 Jun; 247(6):767-73. PubMed ID: 19247683
[TBL] [Abstract][Full Text] [Related]
2. Cigarette smoke-related hydroquinone dysregulates MCP-1, VEGF and PEDF expression in retinal pigment epithelium in vitro and in vivo.
Pons M; Marin-Castaño ME
PLoS One; 2011 Feb; 6(2):e16722. PubMed ID: 21386905
[TBL] [Abstract][Full Text] [Related]
3. Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy.
de Oliveira Dias JR; Rodrigues EB; Maia M; Magalhães O; Penha FM; Farah ME
Br J Ophthalmol; 2011 Dec; 95(12):1631-7. PubMed ID: 21546514
[TBL] [Abstract][Full Text] [Related]
4. Implications of bevacizumab on vascular endothelial growth factor and endostatin in human choroidal neovascularisation.
Tatar O; Shinoda K; Kaiserling E; Claes C; Eckardt C; Eckert T; Pertile G; Boeyden V; Scharioth GB; Yoeruek E; Szurman P; Bartz-Schmidt KU; ; Grisanti S
Br J Ophthalmol; 2009 Feb; 93(2):159-65. PubMed ID: 18838410
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin reduces VEGF expression in retinal pigment epithelium (RPE) and inhibits RPE-induced sprouting angiogenesis in vitro.
Stahl A; Paschek L; Martin G; Gross NJ; Feltgen N; Hansen LL; Agostini HT
FEBS Lett; 2008 Sep; 582(20):3097-102. PubMed ID: 18703055
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium.
Schottler J; Randoll N; Lucius R; Caliebe A; Roider J; Klettner A
Exp Eye Res; 2018 Jun; 171():1-11. PubMed ID: 29522724
[TBL] [Abstract][Full Text] [Related]
7. Minimal effects of VEGF and anti-VEGF drugs on the permeability or selectivity of RPE tight junctions.
Peng S; Adelman RA; Rizzolo LJ
Invest Ophthalmol Vis Sci; 2010 Jun; 51(6):3216-25. PubMed ID: 20042644
[TBL] [Abstract][Full Text] [Related]
8. Nicotine increases the VEGF/PEDF ratio in retinal pigment epithelium: a possible mechanism for CNV in passive smokers with AMD.
Pons M; Marin-Castaño ME
Invest Ophthalmol Vis Sci; 2011 Jun; 52(6):3842-53. PubMed ID: 21330654
[TBL] [Abstract][Full Text] [Related]
9. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia.
Chan WM; Lai TY; Chan KP; Li H; Liu DT; Lam DS; Pang CP
Retina; 2008 Oct; 28(9):1308-13. PubMed ID: 18728623
[TBL] [Abstract][Full Text] [Related]
10. Investigation of the potential utility of a linomide analogue for treatment of choroidal neovascularization.
Abdel-Rahman MH; Yang Y; Salem MM; Meadows S; Massengill JB; Li PK; Davidorf FH
Exp Eye Res; 2010 Dec; 91(6):837-43. PubMed ID: 21055400
[TBL] [Abstract][Full Text] [Related]
11. Decorin inhibits angiogenic potential of choroid-retinal endothelial cells by downregulating hypoxia-induced Met, Rac1, HIF-1α and VEGF expression in cocultured retinal pigment epithelial cells.
Du S; Wang S; Wu Q; Hu J; Li T
Exp Eye Res; 2013 Nov; 116():151-60. PubMed ID: 24016866
[TBL] [Abstract][Full Text] [Related]
12. TNF-α mediates choroidal neovascularization by upregulating VEGF expression in RPE through ROS-dependent β-catenin activation.
Wang H; Han X; Wittchen ES; Hartnett ME
Mol Vis; 2016; 22():116-28. PubMed ID: 26900328
[TBL] [Abstract][Full Text] [Related]
13. Suppression of choroidal neovascularization by vasohibin-1, a vascular endothelium-derived angiogenic inhibitor.
Wakusawa R; Abe T; Sato H; Sonoda H; Sato M; Mitsuda Y; Takakura T; Fukushima T; Onami H; Nagai N; Ishikawa Y; Nishida K; Sato Y
Invest Ophthalmol Vis Sci; 2011 May; 52(6):3272-80. PubMed ID: 21345982
[TBL] [Abstract][Full Text] [Related]
14. Intravenous injection of l-aspartic acid β-hydroxamate attenuates choroidal neovascularization via anti-VEGF and anti-inflammation.
Wu M; Liu Y; Zhang H; Lian M; Chen J; Jiang H; Xu Y; Shan G; Wu S
Exp Eye Res; 2019 May; 182():93-100. PubMed ID: 30917905
[TBL] [Abstract][Full Text] [Related]
15. Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD.
Gammons MV; Fedorov O; Ivison D; Du C; Clark T; Hopkins C; Hagiwara M; Dick AD; Cox R; Harper SJ; Hancox JC; Knapp S; Bates DO
Invest Ophthalmol Vis Sci; 2013 Sep; 54(9):6052-62. PubMed ID: 23887803
[TBL] [Abstract][Full Text] [Related]
16. Different properties of VEGF-antagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells.
Klettner AK; Kruse ML; Meyer T; Wesch D; Kabelitz D; Roider J
Graefes Arch Clin Exp Ophthalmol; 2009 Dec; 247(12):1601-8. PubMed ID: 19597740
[TBL] [Abstract][Full Text] [Related]
17. Clinical and histological findings after intravitreal injection of bevacizumab (Avastin) in a porcine model of choroidal neovascularization.
Lassota N; Prause JU; Scherfig E; Kiilgaard JF; la Cour M
Acta Ophthalmol; 2010 May; 88(3):300-8. PubMed ID: 19416113
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of retinal pigment epithelium tear formation following intravitreal anti-vascular endothelial growth factor therapy revealed by spectral-domain optical coherence tomography.
Nagiel A; Freund KB; Spaide RF; Munch IC; Larsen M; Sarraf D
Am J Ophthalmol; 2013 Nov; 156(5):981-988.e2. PubMed ID: 23972309
[TBL] [Abstract][Full Text] [Related]
19. β2-Adrenergic Receptor Antagonism Attenuates CNV Through Inhibition of VEGF and IL-6 Expression.
Lavine JA; Farnoodian M; Wang S; Darjatmoko SR; Wright LS; Gamm DM; Ip MS; Sorenson CM; Sheibani N
Invest Ophthalmol Vis Sci; 2017 Jan; 58(1):299-308. PubMed ID: 28114591
[TBL] [Abstract][Full Text] [Related]
20. Pigment Epithelium-Derived Factor as a Possible Treatment Agent for Choroidal Neovascularization.
Xi L
Oxid Med Cell Longev; 2020; 2020():8941057. PubMed ID: 32215180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
